AndroGel Lawsuit Alleges Manufacturer Illegally Blocked Generic Versions, Bernstein Liebhard LLP Reports

Share Article

The Firm is evaluating testosterone lawsuits on behalf of men who allegedly suffered serious cardiovascular side effects due to their use of AndroGel and other low testosterone therapies.

Free Case Review
This is just the latest legal action to involve AndroGel. AbbVie is also named in dozens of testosterone treatment lawsuits that have been filed on behalf of men who allegedly suffered life-threatening cardiovascular problems due to their use of AndroGel.

The Federal Trade Commission (FTC) has filed an AndroGel lawsuit (http://www.testosteronelawsuitcenter.com/androgel-lawsuit/) that alleges AbbVie, Teva Pharmaceuticals Industries Ltd., and Besins Healthcare, Inc. illegally blocked lower-cost generic versions of the testosterone treatment from coming to market, Bernstein Liebhard LLP reports. According to the complaint, which was filed on September 8th in the U.S. District Court, Eastern District of Pennsylvania, the Defendants’ actions caused AndroGel users to pay millions of dollars more than necessary for the brand medication. Among other things, the lawsuit charges that AbbVie and Besins filed baseless patent infringement lawsuits against Teva to keep generic versions off the market. AbbVie then entered into an anticompetitive pay-for-delay settlement agreement with Teva to further delay generic drug competition, according to the FTC. (Case 2:14-cv-05151-RK)

“This is just the latest legal action to involve AndroGel. AbbVie is also named in dozens of testosterone treatment lawsuits that have been filed on behalf of men who allegedly suffered life-threatening cardiovascular problems due to their use of AndroGel,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who allegedly have suffered heart attacks, strokes, dangerous blood clots and other serious heart events due to their use of testosterone treatment therapies.

AndroGel Litigation
According to court documents, AndroGel is one of several testosterone replacement therapies named in lawsuits that claim the medications caused dangerous heart problems, including heart attacks and strokes. The majority of these filings are currently pending in a multidistrict litigation underway in the U.S. District Court, Northern District of Illinois, where all federally-filed cases have been consolidated for coordinated pretrial proceedings. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

According to court records, the testosterone litigation began to grow shortly after the U.S. Food & Drug Administration (FDA) announced in January that it was investigating the cardiovascular side effects potentially associated with this class of drugs. Last week, FDA reviewers released a report in advance of the meeting which concluded that there was little evidence to indicate that low testosterone therapy provided any benefits for men who used the drugs to alleviate fatigue, low libido and other symptoms associated with aging. The agency is scheduled to convene an outside panel of advisors on September 17th to discuss this matter, and to explore ways in which cardiovascular risks might be mitigated. *

Men who experienced heart attacks, strokes, or other life-threatening heart problems that were allegedly related to the use of AndroGel or another testosterone treatment may be entitled to compensation for their injury-related damages. To learn more about filing a testosterone lawsuit, please visit Bernstein Liebhard LLP’s website, or call the Firm today at 800-511-5092.

*http://www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/reproductivehealthdrugsadvisorycommittee/ucm412537.pdf, FDA, September 3, 2014

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Felecia L. Stern
Follow us on
Visit website